{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:36:40Z","timestamp":1777671400008,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine High Impact Case Reports"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell production. Although this mechanism is essential for the management of cancer, it may lead to decreased self-tolerance with an autoimmune reaction toward healthy functioning tissue. One of the less commonly reported and less understood immune-related adverse events includes neuromuscular complications. We present a rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab use for cutaneous squamous cell carcinoma of the cheek.<\/jats:p>","DOI":"10.1177\/2324709620916358","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T02:16:17Z","timestamp":1587608177000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab"],"prefix":"10.1177","volume":"8","author":[{"given":"Aakriti","family":"Arora","sequence":"first","affiliation":[{"name":"Mercer University, Macon, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Shere","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Patel","sequence":"additional","affiliation":[{"name":"Mercer University, Macon, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuwan","family":"Gunawardhana","sequence":"additional","affiliation":[{"name":"Florida Atlantic University, Boca Raton, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka","family":"LiFuentes","sequence":"additional","affiliation":[{"name":"Mercer University, Macon, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"bibr1-2324709620916358","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310"},{"key":"bibr2-2324709620916358","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Dong Y","year":"2016","journal-title":"Oncotarget"},{"key":"bibr3-2324709620916358","unstructured":"KEYTRUDA. Approved indications for KEYTRUDA\u00ae (pembrolizumab). https:\/\/www.keytruda.com\/hcp\/approved-indications\/. Accessed March 20, 2019."},{"key":"bibr4-2324709620916358","first-page":"e3371","volume":"10","author":"Manam R","year":"2018","journal-title":"Cureus"},{"key":"bibr5-2324709620916358","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2013.01.005"},{"key":"bibr6-2324709620916358","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"bibr7-2324709620916358","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"bibr8-2324709620916358","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912"},{"issue":"7","key":"bibr9-2324709620916358","first-page":"CD002063","author":"Hughes RA","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Investigative Medicine High Impact Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2324709620916358","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2324709620916358","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2324709620916358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:00:27Z","timestamp":1777449627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2324709620916358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":9,"alternative-id":["10.1177\/2324709620916358"],"URL":"https:\/\/doi.org\/10.1177\/2324709620916358","relation":{},"ISSN":["2324-7096","2324-7096"],"issn-type":[{"value":"2324-7096","type":"print"},{"value":"2324-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2324709620916358"}}